Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received an average rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.8333.

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. Guggenheim increased their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. 5AM Venture Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after purchasing an additional 3,457,913 shares in the last quarter. Millennium Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Zentalis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after purchasing an additional 19,768 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 24.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after purchasing an additional 558,390 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Zentalis Pharmaceuticals by 117.1% during the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after purchasing an additional 835,466 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $3.58 on Tuesday. Zentalis Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $6.95. The company has a market cap of $254.86 million, a P/E ratio of -2.07 and a beta of 1.97. The firm has a 50-day moving average of $3.90 and a 200 day moving average of $2.79.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, equities research analysts expect that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.